Latest filings (excl ownership)
8-A12B/A
Registration of securities on exchange (amended)
3 May 24
8-K
Entry into a Material Definitive Agreement
3 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-A12B
Registration of securities on exchange
17 Apr 24
8-K
Entry into a Material Definitive Agreement
17 Apr 24
8-K
Vanda Pharmaceuticals’ Fanapt® (iloperidone) Receives U.S. FDA Approval
3 Apr 24
8-K
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
7 Mar 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
8-K/A
Special Purpose Abbreviated Financial Statements
16 Feb 24
10-K
2023 FY
Annual report
8 Feb 24
8-K
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7 Feb 24
8-K
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
5 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
15 Dec 23
8-K
Entry into a Material Definitive Agreement
7 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
Other Events
21 Aug 23
10-Q
2023 Q2
Quarterly report
28 Jul 23
8-K
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
27 Jul 23
S-8
Registration of securities for employees
8 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
8-K
Other Events
11 May 23
EFFECT
Notice of effectiveness
8 May 23
S-3/A
Shelf registration (amended)
3 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results
3 May 23
CORRESP
Correspondence with SEC
3 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
8-K
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors
17 Mar 23
8-K
Regulation FD Disclosure
13 Mar 23
8-K
Departure of Directors or Certain Officers
17 Feb 23
UPLOAD
Letter from SEC
16 Feb 23
S-3
Shelf registration
9 Feb 23
10-K
2022 FY
Annual report
9 Feb 23
8-K
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
8 Feb 23
8-K
Other Events
22 Dec 22
8-K
Other Events
16 Dec 22
Latest ownership filings
4
Timothy Williams
6 Mar 24
4
Joakim Wijkstrom
6 Mar 24
4
Mihael Hristos Polymeropoulos
6 Mar 24
4
Kevin Patrick Moran
6 Mar 24
4
Gunther Birznieks
6 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
4
Timothy Williams
21 Feb 24
4
Joakim Wijkstrom
21 Feb 24
4
Kevin Patrick Moran
21 Feb 24
4
Mihael Hristos Polymeropoulos
21 Feb 24
4
Gunther Birznieks
21 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
RENAISSANCE TECHNOLOGIES LLC
13 Feb 24
SC 13G/A
DIMENSIONAL FUND ADVISORS LP
9 Feb 24
SC 13G/A
BlackRock Inc.
23 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
SC 13G/A
BlackRock Inc.
6 Oct 23
4
Joakim Wijkstrom
23 Aug 23
144
Notice of proposed sale of securities
21 Aug 23
4
Stephen Ray Mitchell
11 Aug 23
144
Notice of proposed sale of securities
10 Aug 23
4
Kevin Patrick Moran
1 Aug 23
144
Notice of proposed sale of securities
28 Jul 23
4
Kevin Patrick Moran
20 Jun 23
144
Notice of proposed sale of securities
15 Jun 23
4
Timothy Williams
15 Jun 23
144
Notice of proposed sale of securities
13 Jun 23
4
Anne Sempowski Ward
12 Jun 23
4
Stephen Ray Mitchell
12 Jun 23
4
Tage Honore
12 Jun 23
4
RICHARD W DUGAN
12 Jun 23
4
Phaedra Chrousos
12 Jun 23
4
Tage Honore
17 Mar 23
3
Tage Honore
17 Mar 23
4
Timothy Williams
6 Mar 23
4
Joakim Wijkstrom
6 Mar 23